The global acute disseminated demyelination treatment market is estimated to gather a large share by recording a significant CAGR over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the increasing prevalence of autoimmune diseases across the globe, rising number of cases of the disease, and surge in the total incidences of acute disseminated demyelination among population aged between 0-14 years. According to the National Institutes of Health of the United States, as of now, 23.5 million Americans alone, i.e., more than seven percent of the country’s population suffer from an autoimmune disease. Along with these, detrimental changes in the lifestyle of people all around the world is giving rise to various disorders which lead to muscle weakness, loss of vision and numbness, which in turn is also expected to boost the growth of the market in the upcoming years. Furthermore, rise in technological advancements in the healthcare sector in developed and developing nations, and escalating introduction of new treatment techniques are projected to offer ample growth opportunities to the market in the near future.
The market is segmented based on treatment into corticosteroids, immunoglobulin (IVIg) therapy, plasmapheresis, and others, out of which, the corticosteroids segment is anticipated to hold the largest share in the global acute disseminated demyelination treatment market on account of the wide acceptance of intravenous corticosteroids as first-line treatment for this condition. In addition, the ability of these drugs to effectively reduce inflammation and suppress the immune system is also predicted to drive growth to the market segment in the future. Moreover, on the basis of end user, the segment for hospitals is assessed to acquire the largest share during the forecast period owing to the high emphasis of patients to choose well-established healthcare facility and increasing number of admissions in hospitals around the world. CLICK TO DOWNLOAD SAMPLE REPORT
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
On the basis of geographical analysis, the global acute disseminated demyelination treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in the Asia Pacific is estimated to witness noteworthy over the forecast period on the back of the large patient pool, rising developments in healthcare facilities in emerging economies namely China and India, and growing government investments to improve healthcare infrastructure in the region. Additionally, the market in North America is predicted to gather the largest share over the forecast period, which can be credited to the high healthcare expenditure, and increasing research and development activities to develop effective treatment for acute disseminated demyelination in the region. As per the National Health Expenditure Accounts (NHEA), total healthcare spending in the United States grew 4.6 percent in 2019, reaching $3.8 trillion or $11,582 per person. As a share of the nation's Gross Domestic Product, health spending accounted for 17.7 percent.
The global acute disseminated demyelination treatment market is further classified on the basis of region as follows:
Our in-depth analysis of the global acute disseminated demyelination treatment market includes the following segments:
By End User
FREQUENTLY ASKED QUESTIONS
The major factors driving market growth are increasing prevalence of autoimmune diseases across the globe and rising number of cases of acute disseminated demyelination.
The market is anticipated to attain a significant CAGR over the forecast period, i.e., 2022 – 2030.
Poor health infrastructure in underdeveloped nations is estimated to hamper the market growth.
Asia Pacific will provide more business opportunities for market owing to large patient pool, and rising developments in healthcare facilities in emerging economies of the region.
The major players in the market are Pfizer, Inc., Johnson & Johnson Service, Inc., Novartis AG, Merck & Co. GmbH, and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by treatment, end user, and by region.
The hospitals segment is anticipated to hold largest market size and is estimated to grow at a notable CAGR over the forecast period and display significant growth opportunities.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization